var data={"title":"Mepivacaine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mepivacaine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6532?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mepivacaine-drug-information\" class=\"drug drug_general\">see &quot;Mepivacaine: Drug information&quot;</a> and <a href=\"topic.htm?path=mepivacaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mepivacaine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192931\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Carbocaine;</li>\n      <li>Carbocaine Preservative-Free;</li>\n      <li>Polocaine;</li>\n      <li>Polocaine Dental;</li>\n      <li>Polocaine-MPF;</li>\n      <li>Scandonest 3% Plain</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192932\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Carbocaine;</li>\n      <li>Polocaine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023950\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Local Anesthetic, Injectable</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023975\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mepivacaine-drug-information\" class=\"drug drug_general\">see &quot;Mepivacaine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. The smallest dose and concentration required to produce the desired effect should be used. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dental anesthesia:</b> Children and Adolescents: 3% solution: Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Maximum dose: 5 to 6 mg/kg; maximum total dose: 270 mg. In adults, the dose for single site in upper or lower jaw is 51 mg (one 1.7 mL cartridge)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: American Academy Pediatric Dentistry (AAPD 2015): Maximum dose: 4.4 mg/kg; maximum total dose: 300 mg in any single dental sitting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Local or regional anesthesia (eg, epidural, caudal, or peripheral nerve blocks):</b> Maximum single or total dose given for one procedure: 5 to 6 mg/kg (maximum adult dose per manufacturer: 400 mg); only concentrations &lt;2% should be used in patients &lt;3 years or &lt;14 kg to ensure adequate drug volume for area and to decrease the potential for local anesthetic systemic toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dental anesthesia</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single site in upper or lower jaw: 51 mg as a 3% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infiltration and nerve block of entire oral cavity: 270 mg as a 3% solution; up to 6.6 mg/kg not to exceed 300 mg per appointment. Manufacturer's maximum recommended dose is 400 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following number of dental cartridges (1.7 mL) provide the indicated amounts of mepivacaine dental anesthetic 3%. See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\"># of Cartridges</p>\n            <p style=\"text-indent:0em;\">\n              <b>(1.7 mL)</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Mepivacaine mg</p>\n            <p style=\"text-indent:0em;\">\n              <b>(using 3%)</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">51</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">102</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">153</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">204</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">255</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">306</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">357</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">408</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Local or regional anesthesia (eg, epidural, caudal or peripheral nerve blocks): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum single or total dose given for one procedure: 400 mg; 500 mg if epinephrine has been added (Barash 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum dose per 24 hours: 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cervical, brachial, intercostal, pudendal nerve block: 5 to 40 mL of a 1% solution (maximum: 400 mg) <b>or</b> 5 to 20 mL of a 2% solution (maximum: 400 mg). For pudendal block: Inject <sup>1</sup>/<sub>2</sub> the total dose each side.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transvaginal block (paracervical plus pudendal): Up to 30 mL (both sides) of a 1% solution (maximum: 300 mg). Inject <sup>1</sup>/<sub>2</sub> the total dose into each side.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Paracervical block: Up to 20 mL (both sides) of a 1% solution (maximum: 200 mg). Inject <sup>1</sup>/<sub>2</sub> the total dose into each side. This is the maximum recommended dose per 90-minute procedure; inject slowly with 5 minutes between sides.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Caudal and epidural block (preservative free solutions only): 15 to 30 mL of a 1% solution (maximum: 300 mg) <b>or</b> 10 to 25 mL of a 1.5% solution (maximum: 375 mg) <b>or</b> 10 to 20 mL of a 2% solution (maximum: 400 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infiltration: Up to 40 mL of a 1% solution (maximum: 400 mg); up to 50 mL if epinephrine has been added (maximum: 500 mg) (Barash 2009); an equivalent amount of a 0.5% solution (prepared by diluting the 1% solution with NS) may be used for large areas.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Therapeutic block: 1 to 5 mL of a 1% solution (maximum: 50 mg) <b>or</b> 1 to 5 mL of a 2% solution (maximum: 100 mg)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192914\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carbocaine: 1% (50 mL); 2% (50 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Polocaine: 1% (50 mL); 2% (50 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carbocaine Preservative-Free: 1% (30 mL); 1.5% (30 mL); 2% (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Polocaine-MPF: 1% (30 mL); 1.5% (30 mL); 2% (20 mL) [methylparaben free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [dental use]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carbocaine: 3% (1.7 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Polocaine Dental: 3% (1.7 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Scandonest 3% Plain: 3% (1.7 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192902\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023979\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Before injecting, withdraw syringe plunger to ensure injection is not into vein or artery. Administer slowly in small incremental doses, with frequent aspirations before and during the injection to avoid intravascular injection. Use with caution when there is inflammation and/or sepsis in the region of the proposed injection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Dental: Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2234305\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine 1%, 1.5%, and 2%: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Brief exposure up to 40&deg;C (104&deg;F) does not adversely affect the product. Solutions may be sterilized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine 3% (dental products): Store at &lt;25&deg;C (77&deg;F); do not freeze. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023951\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection 1%, 1.5%, and 2%: Local or regional analgesia; anesthesia by local infiltration, peripheral and central neural techniques including epidural and caudal blocks (FDA approved in pediatric patients [age not specified] and adults); <b>not</b> for use in spinal anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection 3% plain: Local anesthesia for dental procedures by infiltration or nerve block (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192969\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mepivacaine may be confused with bupivacaine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Polocaine may be confused with prilocaine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192967\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Cardiovascular: Bradycardia, cardiac insufficiency, cardiovascular depression, cardiovascular stimulation, heart block, hypertension, hypotension, low cardiac output, syncope, tachycardia, ventricular arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, confusion, convulsions, dizziness, drowsiness, excitement, loss of consciousness, increased body temperature, nervousness, paralysis, persistent anesthesia, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, erythema, pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Fecal incontinence, nausea, oral paresthesia (persistent; involving lips, tongue, and oral tissues), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary incontinence, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Methemoglobinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration), tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, miosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, respiratory depression, sneezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192919\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mepivacaine, other amide-type local anesthetics, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192906\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Familial malignant hyperthermia: May potentially trigger malignant hyperthermia; follow standard protocol for identification and treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including rhythm disturbances, shock, heart block, and hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing, toxic plasma concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acutely ill patients: Use with caution in acutely ill patients; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Preservative-containing solutions: Do not use solutions containing preservatives for caudal or epidural block.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Use with caution when there is inflammation and/or sepsis in the region of the proposed injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate dosing: To avoid serious adverse effects and high plasma levels, the lowest dosage resulting in effective anesthesia should be administered. Repeated doses may cause significant increases in blood levels with each repeated dose due to the possibility of accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with patient status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Test dose: A test dose is recommended prior to epidural administration and all reinforcing doses with continuous catheter technique.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299669\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221552\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13030&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Mepivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192911\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2234302\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Mepivacaine has been used in obstetrical analgesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4412258\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs, state of consciousness, signs of CNS toxicity (lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192905\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mepivacaine is an amide local anesthetic similar to lidocaine. Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192918\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action (route and dose dependent): Range: 3 to 20 minutes; Dental: Upper jaw: 30 to 120 seconds; Lower jaw: 1 to 4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (route and dose dependent): 2 to 2.5 hours; Dental: Upper jaw: 20 minutes; Lower jaw: 40 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~75%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic via N-demethylation, hydroxylation, and glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Neonates: 8.7 to 9 hours; Adults: 1.9 to 3.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (90% to 95% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323371\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carbocaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (50 mL): $8.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (50 mL): $10.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carbocaine Preservative-Free Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (30 mL): $6.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5% (30 mL): $6.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (20 mL): $5.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Polocaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (50 mL): $11.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (50 mL): $11.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Polocaine-MPF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (30 mL): $8.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5% (30 mL): $11.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (20 mL): $9.06</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192922\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Carbocain (DK, SE);</li>\n      <li>Carbocain Dental (NO);</li>\n      <li>Carbocaina (IT);</li>\n      <li>Carbocaine Dental (PL, ZA);</li>\n      <li>Carbocaine HCl (FR);</li>\n      <li>Isocaine (QA);</li>\n      <li>Isocaine 3% (IL);</li>\n      <li>Lentocaine (EC, MX);</li>\n      <li>Meaverin (DE);</li>\n      <li>Mepicaton (QA, SA);</li>\n      <li>Mepicaton 3% (TH);</li>\n      <li>Mepidont (PL);</li>\n      <li>Mepigobbi (AR);</li>\n      <li>Mepivastesin (CZ, HK, IL, PL, SG);</li>\n      <li>Mevan (KR);</li>\n      <li>Scandicain (AT, CH);</li>\n      <li>Scandicaine (BE, LU, NL, QA, SA);</li>\n      <li>Scandinibsa (PT);</li>\n      <li>Scandonest (AE, AU, BG, EE, EG, FI, HU, IE, KR, KW, LT, LV, MT, NZ, RO, SI, SK, UA);</li>\n      <li>Scandonest Sans Vasoconstricteur (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Association of Pediatric Dentists (AAPD), Council on Clinical Affairs. Guideline on use of local anesthesia for pediatric dental patients. Revised 2015. Available at http://www.aapd.org/media/Policies_Guidelines/G_LocalAnesthesia.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barash PG, Cullen BF, Stoelting RK, et al, eds, <i>Clinical Anesthesia</i>, 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carbocaine 3% injection (mepivacaine hydrochloride) [prescribing information]. Cambridge, Ontario, Canada: Novocol Pharmaceutical of Canada, Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carbocaine 1%, 1.5%, and 2% injection (mepivacaine hydrochloride) [prescribing information]. Lake Forest, IL: Hospira, Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cot&eacute; CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Elsevier; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cousins MJ. Neural Blockade. In: <i>Clinical Anesthesia and Pain Medicine</i>. 4th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dodson WE, Hillman RE, and Hillman LS, &ldquo;Brain Tissue Levels in a Fatal Case of Neonatal Mepivacaine (Carbocaine&reg;) Poisoning,&rdquo; <i>J Pediatr</i>, 1975, 86(4):624-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-pediatric-drug-information/abstract-text/1127509/pubmed\" target=\"_blank\" id=\"1127509\">1127509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD. <i>Miller's Anesthesia.</i> 8th ed. Philadelphia, PA: Churchill Livingstone; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-pediatric-drug-information/abstract-text/20216035/pubmed\" target=\"_blank\" id=\"20216035\">20216035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polocaine and Polocaine-MPF 1%, 1.5%, and 2% injection (mepivacaine hydrochloride) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polocaine Dental 3% injection (mepivacaine hydrochloride) [prescribing information]. Cambridge, Ontario, Canada: Novocol Pharmaceutical of Canada, Inc; March 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torres MJ, Garcia JJ, del Cano Moratinos AM, et al, &ldquo;Fixed Drug Eruption Induced by Mepivacaine,&rdquo; <i>J Allergy Clin Immunol</i>, 1995, 96(1):130-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-pediatric-drug-information/abstract-text/7622755/pubmed\" target=\"_blank\" id=\"7622755\">7622755</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13030 Version 92.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192931\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F192932\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1023950\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1023975\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F192914\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F192902\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1023979\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2234305\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1023951\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F192969\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F192967\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F192919\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F192906\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299669\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221552\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F192911\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2234302\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4412258\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F192905\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F192918\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323371\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F192922\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13030|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mepivacaine-drug-information\" class=\"drug drug_general\">Mepivacaine: Drug information</a></li><li><a href=\"topic.htm?path=mepivacaine-patient-drug-information\" class=\"drug drug_patient\">Mepivacaine: Patient drug information</a></li></ul></div></div>","javascript":null}